Develops gene therapies for rare diseases, focusing on genetic disorders and innovative treatment approaches.
Spyre Therapeutics, Inc., a pioneering biotechnology company based in Waltham, Massachusetts, specializes in advancing novel therapeutics for inflammatory bowel disease (IBD) at the preclinical stage. Founded in 2013 and formerly known as Aeglea BioTherapeutics, Inc., the company rebranded to Spyre Therapeutics, Inc. in November 2023, reflecting its commitment to innovative approaches in biopharmaceutical development.
At the forefront of Spyre's pipeline is SPY001, a human monoclonal antibody specifically targeting the a4ß7 integrin, tailored for treating ulcerative colitis and Crohn's disease, the two primary forms of IBD. Complementing this flagship candidate are SPY002, designed to inhibit tumor necrosis factor-like ligand 1A (TL1A), and SPY120, a promising combination therapy comprising SPY001 and SPY002 currently undergoing preclinical evaluation.
Beyond these initiatives, Spyre Therapeutics drives a range of early-stage programs including SPY003, an anti-IL-23 monoclonal antibody, and SPY004, which explores novel mechanisms of action (MOA) in therapeutic antibodies. Additionally, SPY130 and SPY230 represent innovative combinations of antibodies targeting a4ß7, TL1A, and IL-23, underscoring the company's dedication to expanding treatment options for patients suffering from IBD.